...
首页> 外文期刊>The American Journal of the Medical Sciences >Statin underuse and low prevalence of LDL-C control among U.S. Adults at high risk of coronary heart disease
【24h】

Statin underuse and low prevalence of LDL-C control among U.S. Adults at high risk of coronary heart disease

机译:在患有冠心病高风险的美国成年人中他汀类药物的使用不足和LDL-C控制的低患病率

获取原文
获取原文并翻译 | 示例

摘要

Background: Statins reduce the risk of coronary heart disease (CHD) in individuals with a history of CHD or risk equivalents. A 10-year CHD risk >20% is considered a risk equivalent but is frequently not detected. Statin use and low-density lipoprotein cholesterol (LDL-C) control were examined among participants with CHD or risk equivalents in the nationwide Reasons for Geographic and Racial Differences in Stroke study (n = 8812). Methods: Participants were categorized into 4 mutually exclusive groups: (1) history of CHD (n = 4025); (2) no history of CHD but with a history of stroke and/or abdominal aortic aneurysm (AAA) (n = 946); (3) no history of CHD or stroke/AAA but with diabetes mellitus (n = 3134); or (4) no history of the conditions in (1) through (3) but with 10-year Framingham CHD risk score (FRS) >20% calculated using the third Adult Treatment Panel point scoring system (n = 707). Results: Statins were used by 58.4% of those in the CHD group and 41.7%, 40.4% and 20.1% of those in the stroke/AAA, diabetes mellitus and FRS >20% groups, respectively. Among those taking statins, 65.1% had LDL-C <100 mg/dL, with no difference between the CHD, stroke/AAA, or diabetes mellitus groups. However, compared with those in the CHD group, LDL-C <100 mg/dL was less common among participants in the FRS >20% group (multivariable adjusted prevalence ratio: 0.72; 95% confidence interval: 0.62-0.85). Results were similar using the 2013 American College of Cardiology/American Heart Association cholesterol treatment guideline. Conclusions: These data suggest that many people with high CHD risk, especially those with an FRS >20%, do not receive guideline-concordant lipid-lowering therapy and do not achieve an LDL-C <100 mg/dL.
机译:背景:他汀类药物可降低有CHD病史或同等危险病史的个体发生冠心病(CHD)的风险。十年期CHD风险> 20%被认为是等效风险,但经常未被发现。在全国性卒中地理和种族差异原因研究(n = 8812)中,对患有冠心病或风险等同者的参与者进行了他汀类药物的使用和低密度脂蛋白胆固醇(LDL-C)控制。方法:将参与者分为4个互斥组:(1)冠心病病史(n = 4025); (2)无冠心病史,但有中风和/或腹主动脉瘤(AAA)史(n = 946); (3)无冠心病或中风/ AAA史,但有糖尿病(n = 3134);或(4)没有(1)到(3)的病史,但使用第三个成人治疗小组评分系统计算的10年Framingham CHD风险评分(FRS)> 20%(n = 707)。结果:冠心病组中他汀类药物的使用率为58.4%,中风/ AAA,糖尿病和FRS> 20%组中分别为41.7%,40.4%和20.1%。在服用他汀类药物的人群中,有65.1%的LDL-C <100 mg / dL,在冠心病,中风/ AAA或糖尿病组之间没有差异。但是,与CHD组相比,FRS> 20%组的参与者中LDL-C <100 mg / dL较少(多变量校正患病率:0.72; 95%置信区间:0.62-0.85)。使用2013年美国心脏病学会/美国心脏协会胆固醇治疗指南得出的结果相似。结论:这些数据表明,许多冠心病高危人群,特别是FRS> 20%的人群,未接受指南一致的降脂治疗,LDL-C <100 mg / dL。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号